Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature MedicineGlobeNewsWire · 1 day ago
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026GlobeNewsWire · Sep 24, 2026
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Aug 31, 2026
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewsWire · Aug 24, 2026
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewsWire · Aug 13, 2026Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.54 | -$0.43 | Beat |
| May 11, 2026 | -$0.49 | -$0.65 | Miss |
| Mar 12, 2026 | -$0.47 | -$0.49 | Miss |
| Nov 13, 2025 | -$0.62 | -$0.60 | Beat |
| Aug 7, 2025 | -$0.69 | -$0.66 | Beat |
| May 13, 2025 | -$0.67 | -$0.87 | Miss |